This suggests that STAT-3 is not a promising therapeutic target to mitigate IL-27 activity in early life infection.<h4>Importance</h4>The neonatal period is a time in which newborns have increased vulnerability and the highest risk of death from infection. Here, STAT3 is linked to infection.